yahoo_financeOriginal article
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case
Phase 3negativeLevosimendanNegative
AI Analysis
Summary
Tenax Therapeutics' LEVEL trial missed its primary goal for levosimendan, though subgroup data provided some positive signals for the drug candidate.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
LEVEL trial missed primary endpoint
Importance:7/10
Sentiment:
-0.60
Phase 3trial failureprimary endpoint missedlevosimendanLEVEL trial
Related Companies
Read the original article
Published by yahoo_finance on August 11, 2026 6:01 AM